BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 9266986)

  • 1. Human immunodeficiency virus type 1 incorporates both glycosyl phosphatidylinositol-anchored CD55 and CD59 and integral membrane CD46 at levels that protect from complement-mediated destruction.
    Saifuddin M; Hedayati T; Atkinson JP; Holguin MH; Parker CJ; Spear GT
    J Gen Virol; 1997 Aug; 78 ( Pt 8)():1907-11. PubMed ID: 9266986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of CD46, CD55, and CD59 on renal tumor cell lines and their role in preventing complement-mediated tumor cell lysis.
    Gorter A; Blok VT; Haasnoot WH; Ensink NG; Daha MR; Fleuren GJ
    Lab Invest; 1996 Jun; 74(6):1039-49. PubMed ID: 8667608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protection of human nasal respiratory epithelium from complement-mediated lysis by cell-membrane regulators of complement activation.
    Varsano S; Frolkis I; Rashkovsky L; Ophir D; Fishelson Z
    Am J Respir Cell Mol Biol; 1996 Dec; 15(6):731-7. PubMed ID: 8969267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complement control proteins, CD46, CD55, and CD59, as common surface constituents of human and simian immunodeficiency viruses and possible targets for vaccine protection.
    Montefiori DC; Cornell RJ; Zhou JY; Zhou JT; Hirsch VM; Johnson PR
    Virology; 1994 Nov; 205(1):82-92. PubMed ID: 7526538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Host cell-derived complement control proteins CD55 and CD59 are incorporated into the virions of two unrelated enveloped viruses. Human T cell leukemia/lymphoma virus type I (HTLV-I) and human cytomegalovirus (HCMV).
    Spear GT; Lurain NS; Parker CJ; Ghassemi M; Payne GH; Saifuddin M
    J Immunol; 1995 Nov; 155(9):4376-81. PubMed ID: 7594597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of transfected MACIF (CD59) on complement-mediated swine endothelial cell lysis, compared with those of membrane cofactor protein (CD46) and decay-accelerating factor (CD55).
    Miyagawa S; Shirakura R; Nakata S; Izutani H; Matsuda H; Iwata K; Nagasawa S; Terado A; Hatanaka M; Matsumoto M
    Transplant Proc; 1995 Feb; 27(1):328-9. PubMed ID: 7533401
    [No Abstract]   [Full Text] [Related]  

  • 7. Glucose-induced loss of glycosyl-phosphatidylinositol-anchored membrane regulators of complement activation (CD59, CD55) by in vitro cultured human umbilical vein endothelial cells.
    Accardo-Palumbo A; Triolo G; Colonna-Romano G; Potestio M; Carbone M; Ferrante A; Giardina E; Caimi G; Triolo G
    Diabetologia; 2000 Aug; 43(8):1039-47. PubMed ID: 10990082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1.
    Saifuddin M; Parker CJ; Peeples ME; Gorny MK; Zolla-Pazner S; Ghassemi M; Rooney IA; Atkinson JP; Spear GT
    J Exp Med; 1995 Aug; 182(2):501-9. PubMed ID: 7543140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coordinate functions of multiple complement regulating molecules, CD46, CD55, and CD59.
    Loveland BE; Szokolai K; Johnstone RW; McKenzie IF
    Transplant Proc; 1994 Jun; 26(3):1070-1. PubMed ID: 7518104
    [No Abstract]   [Full Text] [Related]  

  • 10. Relative roles of decay-accelerating factor, membrane cofactor protein, and CD59 in the protection of human endothelial cells against complement-mediated lysis.
    Brooimans RA; van Wieringen PA; van Es LA; Daha MR
    Eur J Immunol; 1992 Dec; 22(12):3135-40. PubMed ID: 1280224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of complement membrane regulators membrane cofactor protein (CD46), decay accelerating factor (CD55), and protectin (CD59) in human malignant gliomas.
    Mäenpää A; Junnikkala S; Hakulinen J; Timonen T; Meri S
    Am J Pathol; 1996 Apr; 148(4):1139-52. PubMed ID: 8644856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD55 and CD59 protein expression by Apodemus (field mice) sperm in the absence of CD46.
    Clift LE; Dvorakova-Hortova K; Frolikova M; Andrlikova P; Salman S; Stopka P; Flanagan BF; Johnson PM
    J Reprod Immunol; 2009 Jul; 81(1):62-73. PubMed ID: 19501411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protection of mammalian cells from complement-mediated lysis by transfection of human membrane cofactor protein and decay-accelerating factor.
    Oglesby TJ; White D; Tedja I; Liszewski K; Wright L; Van den Bogarde J; Atkinson JP
    Trans Assoc Am Physicians; 1991; 104():164-72. PubMed ID: 1726964
    [No Abstract]   [Full Text] [Related]  

  • 14. Levels of cell membrane CD59 regulate the extent of complement-mediated lysis of human melanoma cells.
    Brasoveanu LI; Altomonte M; Fonsatti E; Colizzi F; Coral S; Nicotra MR; Cattarossi I; Cattelan A; Natali PG; Maio M
    Lab Invest; 1996 Jan; 74(1):33-42. PubMed ID: 8569195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Membrane-bound regulators of complement activation in uveal melanomas. CD46, CD55, and CD59 in uveal melanomas.
    Goslings WR; Blom DJ; de Waard-Siebinga I; van Beelen E; Claas FH; Jager MJ; Gorter A
    Invest Ophthalmol Vis Sci; 1996 Aug; 37(9):1884-91. PubMed ID: 8759358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59.
    Ziller F; Macor P; Bulla R; Sblattero D; Marzari R; Tedesco F
    Eur J Immunol; 2005 Jul; 35(7):2175-83. PubMed ID: 15971270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antigen-presenting cell exosomes are protected from complement-mediated lysis by expression of CD55 and CD59.
    Clayton A; Harris CL; Court J; Mason MD; Morgan BP
    Eur J Immunol; 2003 Feb; 33(2):522-31. PubMed ID: 12645951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Permanent expression of human CD59 and/or decay-accelerating factor by rat endothelial cells confers protection from human complement-mediated lysis.
    Charreau B; Cassard A; Tesson L; Le Mauff B; Blanchard D; Lublin D; Soulillou JP; Anegon I
    Transplant Proc; 1995 Feb; 27(1):336-7. PubMed ID: 7533404
    [No Abstract]   [Full Text] [Related]  

  • 19. Characterization of a glycosyl-phosphatidylinositol anchor-deficient subline of Raji cells. An analysis of the functional importance of complement inhibitors on the Raji cell line.
    Harris CL; Morgan BP
    Immunology; 1995 Oct; 86(2):311-8. PubMed ID: 7490134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decay-accelerating factor (CD55) protects human immunodeficiency virus type 1 from inactivation by human complement.
    Marschang P; Sodroski J; Würzner R; Dierich MP
    Eur J Immunol; 1995 Jan; 25(1):285-90. PubMed ID: 7531147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.